10.1%, p = 0.443), and men take the combination of the two products less often (3.8% vs
Its best use case may be as an add-on agent to be used with GLP-1 agonists, and not as a standalone alternative to Tirzepatide
More research may help clarify their tolerability in this population
Negro R, Greco EL, Greco G (2019) Alogliptin and gliclazide similarly increase circulating endothelial progenitor cells in type 2 diabetes patients
It is happening right now, in your hippocampus, your cortex, and your basal forebrain, shaping how you think, remember, and adapt
Clinical Status Human RCT | Observational | Animal | In vitro Primarily studied in preclinical and regional aging research contexts, with limited exploratory human data